NEW content online! Ageing, immune fitness and cancer bit.ly/3JdVu0c

HA-PCI is a standard of care for Small Cell Lung Cancer · Secondary endpoint positive · Recommend HA-PCI w/ better cognitive outcomes & no diff OS/intracranial control ascopubs.org/doi/full/10.12…

Los invitamos a participar en una encuesta sobre Juntas de tumores. La encuesta está dirigida a todos los profesionales involucrados en la toma de decisiones en cáncer. Para acceder a la encuesta dar clic en el siguiente link: forms.gle/urf4iQEtZvi3fu…

B7-H3 = consistently high across all #SCLC subtypes (A/N/P/I) — unlike DLL3 & SEZ6! ✅ Uniform high RNA expression ✅ Backs B7-H3-targeted ADCs & TCEs for unselected SCLC ✅ Ifinatamab deruxtecan: 54.8% ORR in ES-SCLC! #LungCancer #PrecisionOncology #ADCs #CancerResearch

Este país perdió la cordura, si es que alguna vez la tuvo.

Treatment of NSCLC after chemoimmunotherapy — are we making headway? Excellent review👇 nature.com/articles/s4157…

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer dlvr.it/TMVKGH

Mindblowing stuff...... Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA science.org/doi/10.1126/sc…

Japan’s national cancer centre now recommends using #LDCT scans for people at high risk of developing #LungCancer. This is a significant milestone and an important shift towards more effective, evidence-based screening for the disease. #LCSM ncc.go.jp/jp/information…

New online! Tracing the evolution of sequencing into the era of genomic medicine bit.ly/45lEYUB

Interesting look at screen failures in early phase trials at 3 French centers ESMO Open (n=202). Screen fail rate 22%: 29% due to radiologic findings (usually brain metastases, no measurable disease), 24% biologic, 11% administrative, 12% due to PS. esmoopen.com/article/S2059-…

nature.com/articles/s4157…

🚨 New paper alert👉🏼Pleased to share IASLC #MTB recommendations in JTO & JTO CRR! Kudos to the amazing Mihaela Aldea for integrating so many inputs (just look at the author list, has so many awesome colleagues in #LungCancer #PrecisionOncology). This paper shapes a framework

Next-gen immunotherapies are tackling resistance to ICIs in lung cancer, with bispecific antibodies like ivonescimab (PD-1×VEGF) and tarlatamab (DLL3×CD3) paving the way for new standards of care. 📖 NatureRevClinOncol DOI 👉🏻 doi.org/10.1038/s41571… #CánCare #NSCLC #SCLC

🎉This is an exceptional review of tumor biology and immunotherapy resistance in NSCLC. Highly recommended reading. Some key points about KEAP1, STK11, SMARCA4 biology at a high level🧵

Estudo multicêntrico N=958 ✅️Algoritmo de deep learning capaz de prever resposta a ICI em CPCNP avançado (AUC 0,75/0,66), superando TMB, TILs e PD-L1. 📌Preditor independente de SLP (HR 0,56) e SG (HR 0,53). Biomarcadores digitais ajudarão a guiar tratamenyo? #JAMAOncol

Finally, new guidelines for immunotherapy for lung cancer and mesotheliomas! However, treatment is evolving very fast!

Want to dive into patterns, biomarkers and strategies to overcome primary and acquired resistance to immunotherapy in lung cancer? Check out our review just published on NatureRevClinOncol. A master piece from Martin Reck Fabrice Barlesi and many other kols! nature.com/articles/s4157…

Treatment of NSCLC after chemoimmunotherapy — are we making headway? | Nature Reviews Clinical Oncology nature.com/articles/s4157…